BIDE Pharmatech 毕得医药
17 significant filings since 31 May 2026: 1 on change of control, 6 on equity incentive and 6 on change of interest, and 2 other kinds. The latest, on 10 Sep 2026: 股东减持计划时间届满暨减持股份结果公告.
自 31 May 2026 起有 17 份重大公告：change of control 1 份、equity incentive 6 份、change of interest 6 份，另有 2 类。最新一份（10 Sep 2026）：股东减持计划时间届满暨减持股份结果公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥80.76 · Low 最低 ¥66.00 · −7.69% on the previous close of ¥80.76The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 余汝意,石启正 | Buy 买入 | 7 May 2026 | 2 | — |
| 太平洋 | 周豫,张崴 | Buy 买入 | 1 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。